Details for Patent: 12,042,489
Which drugs does patent 12,042,489 protect, and when does it expire?
Patent 12,042,489 protects GALAFOLD and is included in one NDA.
This patent has one hundred and fifty-two patent family members in twenty-seven countries.
Summary for Patent: 12,042,489
| Title: | Methods of treating Fabry patients having renal impairment |
| Abstract: | Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day. |
| Inventor(s): | Jeff Castelli, Elfrida Benjamin |
| Assignee: | Amicus Therapeutics Inc |
| Application Number: | US18/326,279 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,042,489 |
|
Patent Claim Types: see list of patent claims | Use; |
Recent additions to Drugs Protected by US Patent 12,042,489
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therap Us | GALAFOLD | migalastat hydrochloride | CAPSULE | 208623 | Aug 10, 2018 | RX | Yes | 12,042,489 | Y | ⤷ Start Trial | U-2371 | THE TREATMENT OF FABRY PATIENTS | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 12,042,489
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therap Us | GALAFOLD | migalastat hydrochloride | CAPSULE;ORAL | 208623-001 | Aug 10, 2018 | RX | Yes | Yes | 12,042,489 | ⤷ Start Trial | Y | THE TREATMENT OF FABRY PATIENTS | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,042,489
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 111971 | ⤷ Start Trial | |||
| Argentina | 131106 | ⤷ Start Trial | |||
| Argentina | 131107 | ⤷ Start Trial | |||
| Australia | 2009214648 | ⤷ Start Trial | |||
| Australia | 2014221321 | ⤷ Start Trial | |||
| Australia | 2016206297 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
